Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Matthew Titlow has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending action is under the review of 1 distinct examiner, YAMASAKI, ROBERT J. As the only examiner with an active case for the company, YAMASAKI, ROBERT J is the busiest examiner with 1 pending office action.
The portfolio's current activity is confined to 1 distinct art unit. This single art unit and the 1 distinct examiner represent the entirety of the company's pending matters at the USPTO. The 1 pending office action is the sole focus of the company's current patent prosecution efforts, requiring no coordination across different administrative divisions.
With 1 pending office action, the company's engagement is highly centralized. Practitioners can focus exclusively on the examination patterns of YAMASAKI, ROBERT J within the 1 art unit involved. The 1 pending action in the Biotechnology & Pharmaceuticals area is the only active matter for Matthew Titlow, allowing for a concentrated legal strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YAMASAKI, ROBERT J | 1 | 67.4% | +44.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19318013 | AUTOBIOTIC COMPOSITIONS AND METHOD FOR PROMOTING HEALTHY GUT MICROBIOME | YAMASAKI, ROBERT J | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19318013 | AUTOBIOTIC COMPOSITIONS AND METHOD FOR PROMOTING HEALTHY GUT MICROBIOME | YAMASAKI, ROBERT J | 1657 | §103DP | Non-Final OA | — | Pending | Sep 03, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMatthew Titlow has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert J Yamasaki has the most, with 1 of Matthew Titlow's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
